Catherine Stehman-Breen, Chroma Medicine CEO
March 1, 2023 06:00 AM ESTUpdated 06:38 AM
Financing
Bioregnum
Cell/Gene Tx

A gene edit­ing 3.0 play­er goes deep on cash, fron­tier sci­ence to put pre­ci­sion epi­ge­net­ics to the big test

Is­si Rozen is as deeply em­bed­ded in­to the gene edit­ing field as any­one in the buzzy Cam­bridge, MA biotech hub. As chief busi­ness of­fi­cer and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Roche sep­a­rates CFO, in­for­mat­ics posts; Lil­ly ex­ecs land at Kail­era, Neu­ro­crine

Ver­tex's non-opi­oid pain drug is ap­proved by FDA, bring­ing first of new class to mar­ket

Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Ab­b­Vie rais­es Skyrizi and Rin­voq es­ti­mates, pre­dicts $31B in 2027 sales

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times